Emergent Biosolutions Return on Investment 2010-2022 | EBS

Current and historical return on investment (ROI) values for Emergent Biosolutions (EBS) over the last 10 years.
Emergent Biosolutions ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-03-31 $0.26B $2.38B 11.06%
2021-12-31 $0.35B $2.43B 14.83%
2021-09-30 $0.33B $2.34B 14.24%
2021-06-30 $0.43B $2.37B 18.83%
2021-03-31 $0.54B $2.36B 24.82%
2020-12-31 $0.43B $2.29B 21.17%
2020-09-30 $0.25B $2.10B 13.00%
2020-06-30 $0.26B $1.96B 13.97%
2020-03-31 $0.13B $1.84B 7.03%
2019-12-31 $0.12B $1.89B 6.32%
2019-09-30 $0.05B $1.85B 2.67%
2019-06-30 $-0.00B $1.82B -0.13%
2019-03-31 $0.07B $1.72B 5.29%
2018-12-31 $0.09B $1.80B 7.70%
2018-09-30 $0.13B $0.98B 13.96%
2018-06-30 $0.16B $0.95B 17.15%
2018-03-31 $0.10B $0.90B 11.10%
2017-12-31 $0.13B $0.93B 14.02%
2017-09-30 $0.12B $0.91B 14.12%
2017-06-30 $0.11B $0.87B 13.07%
2017-03-31 $0.10B $0.86B 11.59%
2016-12-31 $0.11B $0.84B 12.09%
2016-09-30 $0.14B $0.80B 15.72%
2016-06-30 $0.17B $0.92B 18.56%
2016-03-31 $0.19B $0.91B 21.75%
2015-12-31 $0.14B $0.91B 16.74%
2015-09-30 $0.13B $0.86B 16.17%
2015-06-30 $0.10B $0.82B 12.61%
2015-03-31 $0.09B $0.79B 11.24%
2014-12-31 $0.09B $0.80B 11.86%
2014-09-30 $0.04B $0.76B 5.32%
2014-06-30 $0.02B $0.74B 3.78%
2014-03-31 $0.03B $0.73B 5.38%
2013-12-31 $0.04B $0.55B 8.31%
2013-09-30 $0.04B $0.52B 8.71%
2013-06-30 $0.04B $0.51B 7.25%
2013-03-31 $0.03B $0.49B 6.12%
2012-12-31 $0.03B $0.50B 6.19%
2012-09-30 $0.05B $0.49B 10.90%
2012-06-30 $0.04B $0.48B 9.27%
2012-03-31 $0.05B $0.47B 12.11%
2011-12-31 $0.03B $0.47B 7.28%
2011-09-30 $0.02B $0.43B 4.89%
2011-06-30 $0.04B $0.41B 10.54%
2011-03-31 $0.04B $0.39B 9.95%
2010-12-31 $0.07B $0.40B 22.58%
2010-09-30 $0.04B $0.32B 14.38%
2010-06-30 $0.02B $0.30B 6.32%
2010-03-31 $0.03B $0.29B 9.52%
2009-12-31 $0.04B $0.29B 15.28%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.599B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00